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Tissue rejection occurs subsequent to the recognition of foreign antigens via receptor-ligand contacts
between APC (antigen presenting cells) and T cells, resulting in initialization of signaling cascades and T
cell proliferation. Bioengineering of donor cells by the covalent attachment of methoxypolyethylene
glycol (mPEG) to membrane proteins (PEGylation) provides a novel means to attenuate these interactions
consequent to mPEG-induced charge and steric camouﬂage. While previous studies demonstrated that
polymer-mediated immunocamouﬂage decreased immune recognition both in vitro and in vivo, these
studies monitored late events in immune recognition and activation such as T cell proliferation.
Consequently little information has been provided concerning the early cellular events governing this
response. Therefore, the effect of PEGylation was assessed by examining initial cellecell interactions,
changes to activation pathways, and apoptosis to understand the role that each may play in the
decreased proliferative response observed in modiﬁed cells during the course of a mixed lymphocyte
reaction (MLR). The mPEG-modiﬁed T cells resulted in signiﬁcant immunocamouﬂage of lymphocyte
surface proteins and decreased interactions with APC. Furthermore, mPEG-MLR exhibited decreased
NFkB pathway activation, while exhibiting no signiﬁcant differences in degree of cell death compared to
the control MLR. These results suggest that PEGylation may prevent the direct recognition of foreign
alloantigens by decreasing the stability and duration of initial cellecell interactions.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite tissue matching to major blood groups and HLA anti-
gens, rejection of foreign tissues remains a major problem in
transfusion and transplantation medicine [1e3]. This is due to both
the antigenic diversity of human cells, which impedes tissue
matching, and the complex nature of the immune response
following allorecognition of foreign tissues. Together, these factors
negatively impact the acute and long-term viability and function of
the transplanted tissues as well as the quality of life of the recipient.
To overcome these obstacles, successful tissue and organ trans-
plantation are largely dependent on the use of broadly acting andand the Centre for Blood
Centre, 2350 Health Sciences
Ltd. This is an open access article utoxic immunosuppressant drugs.
Immunosuppressant drugs typically exhibit broad inhibition,
suppressing helpful as well as harmful responses, resulting in se-
vere side effects such as cancer, infection, and direct allograft
damage due to drug toxicity [4,5]. Moreover, many immunosup-
pressant drugs work by inhibiting downstream effector responses,
after allorecognition has occurred. While some therapeutics inhibit
initial activation events by targeting adhesion and costimulatory
receptors, the redundant nature of receptors may decrease the ef-
ﬁcacy of these drugs for preventing graft rejection [6]. As a
consequence, receptor speciﬁc therapies are often used in combi-
nation with other costimulatory blocking agents or non-speciﬁc
broadly acting immunosuppressant drugs [6]. However, prevent-
ing allorecognition and inducing immune quiescence would be
preferable to the cytotoxic drugs currently used to prevent tissue
rejection. As such, novel methods to prevent the recognition and
rejection of foreign tissues would be beneﬁcial.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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membrane proteins may provide a means of achieving this goal.
Approved PEGylated proteins have been widely used for drug de-
livery to enhance bioavailability and decrease immune responses
[7,8]. More recently, the direct PEGylation of intact cells (e.g., RBC,
WBC) [9e14] and tissues (e.g., pancreatic islets) [15e18] have been
examined. As demonstrated in these studies, PEGylated red blood
cells (RBC) resulted in efﬁcient camouﬂage of non-ABO RBC anti-
gens with no signiﬁcant effect on morphology, lysis, or murine
in vivo survival, while PEGylated leukocytes (WBC) prevented
allorecognition and T cell activation both in vitro and in vivo. Of
particular interest, the leukocyte ﬁndings strongly suggest that
PEGylated cells and tissues may have signiﬁcant utility in trans-
plantation research, where prevention of allorecognition is critical.
PEGylation, unlike current immunosuppressive drugs, would be a
novel and non-toxic means to prevent initial allorecognition events
via the global camouﬂage of allogeneic cells.
While recent studies suggest that PEGylated allogeneic leuko-
cytes induced an immunosuppressive state by altering the differ-
entiation, proliferation, and environmental milieu both in vitro and
in a murine model [13], they did not fully deﬁned the initial mo-
lecular mechanisms governing these events. Indeed, studies to date
have monitored late events in T cell activation such as proliferation
and cytokine secretion. Although valuable, these studies do not
provide the dynamic information on early T cell allorecognition and
activation events. Therefore, the effect of PEGylation was assessed
by examining initial cellecell interactions, changes to activation
pathways, and apoptosis to understand the role that each may play
in the decreased proliferative response observed in modiﬁed cells
during the course of a MLR. Understanding the mechanism of the
induced immune quiescent state by immunocamouﬂage is impor-
tant for producing improved and/or novel cellular blood products.2. Methods and materials
2.1. Cell collection
All experiments using human blood cells were done with the
approval of the University of British Columbia Clinical Research
Ethics Board and in accordance with the Declaration of Helsinki.
Following informed consent, donor whole blood was collected in
heparinized Vacutainer® blood tubes (BD, Franklin Lakes, NJ). Pe-
ripheral blood mononuclear cells (PBMC) were isolated using
Histopaque-1077 (SigmaeAldrich, St. Louis, MO, USA) according to
manufacturer's protocol.2.2. Generation of monocyte derived dendritic cells (moDC)
moDC were prepared as previously described [14]. Brieﬂy,
freshly prepared PBMC were seeded at 5  106 cells/ml in AIM V
medium (Gibco, Invitrogen, Grand Island, NY, USA). After 3 h in-
cubation (37 C, 5% CO2), non-adherent cells were removed by
washing. The remaining monocyte rich adherent cells were incu-
bated in AIM V medium supplemented with IL-4 (100 ng/ml) and
GM-CSF (50 ng/ml) (R&D Systems, Minneapolis, MN, USA). IL-4 and
GM-CSF was added again on day 3. On day 6, cells were washed
twice and suspended at 5  105 cells/ml in AIM V medium sup-
plemented with IL-4, GM-CSF and maturation/activating cytokines
TNF-a (5 ng/ml), IL-1b (5 ng/ml), IL-6 (150 ng/ml) (R&D systems
Inc., Minneapolis, MN, USA) and prostaglandin E2 (1 mg/ml) (Sig-
maeAldrich, St. Louis, MO, USA). Mature moDC were harvested on
day 7 and assessed by ﬂow cytometry for maturationmarkers CD80
and CD86 (BD Biosciences, San Jose, CA, USA) prior to downstream
assays.2.3. Polymer species and cell derivatization
Polymer modiﬁcation of donor leukocytes was done using suc-
cinimidyl valerate activatedmPEG (mPEG; 5, 20 and 30 kDa; Laysan
Bio Incorporated, Arab, AL, USA) as previously described [13,19].
Isolated PBMC were suspended to 4  106 cells/ml in mPEG buffer
(50 mM K2HPO4, 105 mM NaCl, pH 8.0) with desired amount of
mPEG (5, 20, 30 kDa) to reach appropriate grafting concentration
(0e4 mM). The reaction was performed for 1 h at room tempera-
ture. PBMC were stained with trypan blue (Invitrogen, Grand Is-
land, NY, USA) and enumerated using a hemocytometer.
2.4. Surface marker analysis
Freshly isolated control or mPEG-modiﬁed PBMC were assessed
for immunocamouﬂage efﬁcacy by exclusion of ﬂuorescently
labeled antibodies to leukocyte cluster of differentiation (CD)
markers. Surface marker analysis was examined via ﬂow cytometry
as previously described [11,13,19e21]. PBMC cell suspensions were
stained with anti-CD11a FITC, anti-CD25 PE, anti-CD62L PE or anti-
CD71 FITC according to manufacturer's instructions (BD Bio-
sciences, San Jose, CA, USA). Unstained cells and isotype control
antibodies were utilized for each ﬂuorophore to determine the
degree of non-speciﬁc binding and background ﬂuorescence.
Analysis of the efﬁcacy of immunocamouﬂage was based on
percent positive cell (PPC) values. For all studies, a minimum of
20,000 events per sample was collected.
2.5. Mixed lymphocyte reactions
To assess the effects of polymer modiﬁed leukocytes during
allorecognition, one of the two disparate PBMC population was
modiﬁed with polymer (20 and 30 kDa mPEG; 0e2 mM) as pre-
viously described [13,19]. An equal number of cells from two
disparate PBMC populations were suspended in AIM V medium
(2  106 cells/ml) and incubated in a humidiﬁed, 5% CO2 incubator
at 37 C. Cells were harvested for downstream assays at various
timepoints as indicated. For proliferation and conjugation assays,
cells were stained with amine reactive ﬂuorescent probes prior to
cell modiﬁcation with polymer.
2.6. CFSE proliferation assay
The proliferative response of PBMC was used to assess the ef-
fects of cell modiﬁcation on allorecognition (MLR) as well as the
response to mitogen challenge (PHA) as previously described
[13,19]. Freshly isolated human PBMCs were stained with carbox-
yﬂuorescein diacetate succinimidylester (CFSE; Cell Trace- Molec-
ular Probes, Invitrogen, Carlsbad, CA, USA) according to
manufacturer's instructions. Following CFSE staining, PBMC were
derivatized with mPEG as described above. For mitogen stimula-
tion, PHA was added at 2 mg/ml. Proliferation of the CD3þCD4þ
populationwas assessed by ﬂow cytometry on days 7, 10 and 14 for
the MLR and day 5 for PHA stimulation. The CD3þCD4þ population
was determined using anti-CD3 PE and anti-CD4 APC antibodies
(BD biosciences, San Jose, CA, USA) according to manufacturer's
instructions. Data acquisition and analysis was performed using
Cell Quest Software as previously described.
2.7. Time-lapse microscopy
To investigate the effects of PEGylation on the cellecell inter-
action necessary for allopresentation and alloproliferation,
matured moDC and allogeneic control or mPEG-modiﬁed PBMC
(20 kDa mPEG; 2.0 mM) were co-cultured in RPMI supplemented
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(moDC: PBMC), and seeded on chambered cover glass (Becton
Dickinson, Franklin Lakes, NJ, USA) at a cell concentration of
5  105 cells/ml in a 37 C heated humidity chamber. Images were
taken at 200  magniﬁcation every 20 s for 90 min using a Nikon
Eclipse Ti microscope mounted with a camera (Digital sight DS-U3)
and analyzed using NIS-elements software. Cell trajectories were
obtained by tracking the location of moDC in unmodiﬁed and
modiﬁed co-cultures every 20 s over a time course of 90 min using
NIS-elements software.
2.8. Cell conjugation assay
To quantify the effects of mPEGmodiﬁcation on cell conjugation
events, matured moDC were co-cultured with PEGylated allogeneic
human PBMC, syngeneic, or unmodiﬁed allogeneic control PBMC.
The number of conjugates formed after 20 min was assessed by
ﬂow cytometry. Enumeration of cell conjugation events was
modiﬁed from Grebe et al. [22] Brieﬂy, PBMC and moDC were
stained with amine reactive ﬂuorescent probes at a ﬁnal concen-
tration of 0.5 mM CFSE and 2.5 mM Far Red DDAO (CellTrace, Mo-
lecular Probes, Invitrogen, Eugene, OR, USA) per 2  106 cells,
respectively. Cells were washed 3 in excess RPMI to remove any
unincorporated stain. Following CFSE staining, PBMC were deriv-
atized with mPEG (20 kDa) at 0e2 mM grafting concentrations.
MoDC and human PBMC co-cultures were suspended in AIM V
medium in a ratio of 1:10 (moDC:PBMC) for a ﬁnal concentration of
1 107 cells/ml. Co-cultures were centrifuged brieﬂy and incubated
at 37 C, 5% CO2, and 95% humidity for 20 min to allow conjugation
of cells. Cells were ﬁxed by addition of 2% methanol free formal-
dehyde. The double-staining population (CFSE þ Far Red-DDAOþ)
was examined to determine the percentage of cell conjugation
using ﬂow cytometry as previously described.
2.9. Real-time PCR (qPCR)
o examine the effects of mPEG-PBMC modiﬁcation on NFkB
signaling during a MLR, the mRNA expression of NFkB target genes
was examined in control and mPEG modiﬁed MLR (20 kDa;
2.0 mM) at 2, 6 and 24 h. Cells were harvested and placed on ice.
Total mRNA was extracted using MirVana Paris Kit (Ambion Life
Technologies, Carlsbad, CA, USA) according to manufacturer's in-
structions. The concentration of RNA eluent was determined by
nanodrop. cDNA synthesis and genomic DNA elimination from total
RNA preparation was done using RT2 First Strand kit (Qiagen,
Limberg, Netherlands), according to manufacturer's protocol. qPCR
was performed using Human NFkB Signaling Targets RT2 PCR array,
RT2 SYBR Green Mastermix (Qiagen, Limberg, Netherlands) and
Applied Biosystems StepOnePlus (Life Technologies, Carlsbad, CA,
USA) according to manufacturer's protocols. Threshold, baseline
and CT values were calculated using StepOnePlus software (v.2.1).
Analysis of PCR results was performed using Qiagen GeneGlobe
data analysis.
2.10. Preparation of protein lysates
Expression of IL2Ra, IL2Rb, and IL1R2 were examined on day 4
and 7 of a MLR by western blot. For IL1R2, both cell culture su-
pernatants and cells were harvested. IL1R2 from cell culture su-
pernatant was concentrated using protein A/G PLUS-agarose
immunoprecipitation reagent (Santa Cruz Biotechnology, Dallas TX,
USA) according to manufacturer's instruction. Cells were washed
2 in ice cold PBS and lysed with RIPA buffer (150 mM NaCl, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 50 mM Tris pH 8.0 and 1Halt™ protease and phosphataseinhibitor cocktail) on ice for 30 min. The lysate was centrifuged at
14,000  g, 4 C for 30 min. The supernatant (total cell extract) was
removed and frozen at 80 C. Protein concentrations of all lysates
were determined by the BCA protein assay (Thermo Scientiﬁc
Pierce, Waltham, MA, USA) according to manufacturer's
instructions.
2.11. SDS-PAGE and western blot
Control and experimental lysates (20 mg) as well as molecular
weight standards (Dual Color precision plus protein standards Bio-
Rad Laboratories, Hercules, CA, USA)were separated on 10% sodium
dodecyl sulfate-polyacrylamide (SDS-PAGE) gels and transferred
for 60 min onto Immun-Blot PVDF membranes (Bio-Rad Labora-
tories, Hercules, CA, USA). Membranes were blocked overnight in
5% non-fat milk at 4 C with rocking, washed 3 in tris buffered
saline with tween (TBST) and probed with primary antibodies
against IL1R2 (AF-263-NA) (R&D Systems, Minneapolis, MN, USA)
and IL2a (ab61777), IL2b (ab137699) and anti-beta actin (ab88229)
used as a loading control (Abcam, Cambridge, MA, USA). Mem-
branes were washed 3 in TBST, followed by labeling with Licor
IRDye® secondary antibodies (Licor, Lincoln, NE, USA) for 1 h. Pro-
tein band signals were assessed using Licor Odyssey and intensities
were analyzed by densitometry and normalized to actin loading
control using Odyssey software v3.0.
2.12. Assessment of polymer induced apoptosis and necrosis
Flow cytometry was used to assess early and late apoptotic/
necrotic events in mPEG-modiﬁed PBMC (20 kDa; 0e2 mM) and
during allogeneic (MLR) challenge over 72 h. To monitor apoptotic
events, control and derivatized PBMC were incubated with a cell
permeable peptide conjugated to a ﬂuorescent caspase 3/7 probe
(CellEvent® Caspase-3/7 Green Flow Cytometry Assay, Molecular
Probes, Invitrogen, Eugene, OR, USA) and Sytox (Molecular Probes
Invitrogen, Eugene, OR, USA) according to manufacturer's pro-
tocols. Flow cytometry and analysis was performed as described
above. Anisomycin, a potent apoptosis inducer, served as the pos-
itive control.
2.13. Statistical analysis
All results were expressed as means ± standard error mean
(SEM). A minimum of 3 independent replicates was completed for
all studies in duplicate. In some instances representative images
were presented (i.e., microscopy). Data analysis was conducted
using SPSS v.16.0 statistical software (Statistical Products and Ser-
vices Solutions, Chicago, IL, USA). For signiﬁcance, a minimum p-
value of <0.05 was used. For comparison of two mean values, an
independent variable t-test was performed. For comparison of
three or more means, a one-way analysis of variance (ANOVA) was
performed followed by Post hoc analysis using the Tukey test.
3. Results
3.1. Immunocamouﬂage of surface markers
A successful alloresponse requires signiﬁcant interactions initi-
ated at the cell surface level. To this end, the efﬁcacy of immuno-
camouﬂage on multiple cell surface proteins involved in adhesion
(CD11a and CD62L), activation and proliferation (CD25 and CD71),
and allorecognition and costimulation (CD3, CD4 and CD28) were
examined by ﬂow cytometry. As demonstrated in Fig. 1, the modi-
ﬁcation of PBMCwith mPEG resulted in a polymer size and grafting
concentration dependent decreases in detection of multiple cell
Fig. 1. PEGylation resulted in the global immunocamouﬂage of lymphocyte surface proteins crucial for effective immune recognition. Covalent modiﬁcation of PBMC with mPEG
resulted in a dose and size dependent decrease in percent positive cells (PPC) for surface proteins involved in adhesion (CD11a, CD62L), allorecognition and costimulation (CD3, CD4,
and CD28) as well as activation and proliferation (CD25, CD71). Results are given as PPC ± SEM of a minimum of three independent experiments. The mean value for unmodiﬁed
cells incubated with antibody was set to equal 100%. Surface camouﬂage of CD3, CD4, and CD28 modiﬁed from Kyluik-Price et al. [19].
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including; CD11a (integrin), CD62L (selectin), CD25 (high afﬁnity
IL2 receptor), CD71 (transferrin receptor) and, as previously re-
ported, T cell receptors complex proteins (CD3, CD4 and CD28)
[19,21]. The polymer-modiﬁed PBMC demonstrated signiﬁcant re-
ductions in percent positive cells (PPC) by 4.0 mM grafting con-
centrations (p < 0.05) for all polymer lengths, compared to the
control, suggesting that the grafted polymer induced an effective
global surface immunocamouﬂage. The longer polymers (20 and
30 kDa), however, resulted in signiﬁcantly improved immunoca-
mouﬂage compared to the shorter (5 kDa) polymers at moderate
grafting concentrations. For example, detection of CD11a at 2.0 mM
with the 5 kDa polymer resulted in a PPC of 57.2 ± 11.3%, while the
20 kDa and 30 kDa polymers reduced PPC to 30.7 ± 6.8% and
35.1 ± 8.4%, respectively. Similarly, the detection of CD62L at
2.0 mM grafting concentrations was 82.6 ± 4.5% using the 5 kDa,
31.2 ± 6.3% using the 20 kDa and 24.8 ± 6.6% using the 30 kDa
polymer. The size dependent nature of immunocamouﬂage arises
from both the protein topography as well as the Flory radius of the
grafted polymer (RF for 5 and 20 kDa ¼ 6.0 and 13.8 nm, respec-
tively), which governs the surface area of polymer exclusion [21,23].3.2. Lymphocyte stimulation, cell conjugation, and apoptosis
To assess the downstream effects of surface camouﬂage, theproliferative response of modiﬁed PBMC to allogeneic cells (MLR)
and mitogens (PHA) was examined (Fig. 2A). PEGylation of PBMC
with 20 kDa mPEG (0e2 mM) resulted in a signiﬁcant dose
dependent decrease in the proliferation of CD3þ/CD4þ lympho-
cytes. These results demonstrate that polymer-mediated camou-
ﬂage of surface proteins prevents cell activation via both large
mitogens such as PHA (m.w. 126 kDa) and receptor-ligand binding
of stimulatory cells (antigen presenting cell; APC) involved in an
alloresponse. To further assess the effects of polymer-mediated
immunocamouﬂage on cellecell interactions (i.e., cell conjuga-
tion) between lymphocytes and APCs, human PBMC and moDC
(human monocyte derived dendritic cells; APC) were labeled with
disparate ﬂuorescent dyes and cell conjugates were quantiﬁed us-
ing ﬂow cytometry. As demonstrated in Fig. 2B, covalently grafted
20 kDa mPEG resulted in a signiﬁcant (p < 0.03 at  0.5 mM) dose
dependent decrease in the number of cell conjugates. Moreover, at
the 2.0 mM polymer grafting concentration, cell conjugation was
signiﬁcantly reduced to 1.04 ± 0.1% (p < 0.001) from the control
value (2.36± 0.2%). Indeed, at grafting concentrations2.0mM, the
number of PEGylated PBMC and allogeneic moDC conjugates were
virtually identical to, or actually reduced, relative to the syngeneic
co-culture (1.05 ± 0.1%). Importantly, soluble PEG had no inhibitory
effect on allogeneic cell conjugation demonstrating that membrane
grafting was essential to the inhibitory effects of mPEG.
While polymer mediated inhibition of cellecell interactions
Fig. 2. Leukocyte PEGylation (20 kDa mPEG) decreased alloproliferation and cell conjugate formation during allogeneic challenge with no signiﬁcant effects on cell viability. Panel
A: PEGylation of PBMC with 20 kDa mPEG (0e2 mM) resulted in a signiﬁcant dose dependent decrease in the proliferation of CD3þ/CD4þ lymphocytes consequent to both
allogeneic (MLR) and mitogen (PHA) challenge. Cell proliferation was assessed on day 14 of the MLR and day 5 of PHA challenge. Results (n ¼ 4) are expressed as the percent
(mean ± SEM) of unmodiﬁed cell proliferation normalized to equal 100%. Panel B: PEGylated PBMC demonstrated a signiﬁcant dose dependent decrease in the number of cell
conjugates (p < 0.02 at  0.5 mM). Shown are the percentages of double staining cells over various polymer-grafting concentrations (0e4 mM). The number of PEGylated PBMC and
allogeneic moDC conjugates were not signiﬁcantly different from the syngeneic co-culture at all polymer lengths and concentrations (p > 0.05). Results are expressed as
mean ± SEM (n ¼ 4). Panels C and D: Cell death was slightly increased in mPEG-MLR 24 h (activation phase), but not signiﬁcantly different from control MLR at > 2 h (p > 0.05), for
either early (C) and late apoptotic markers (D) compared to the resting unmodiﬁed control PBMC at  2 h. Results are expressed as mean ± SEM (n ¼ 3).
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during MLRs (Fig. 2A), weak costimulation (e.g., via CD28) or loss of
survival factor stimulation (e.g., IL-2) could induce cell death (either
apoptosis or necrosis) thus accounting for the loss of alloprolifer-
ation. To determine whether cell death arising from polymer
grafting resulted in the loss of alloproliferation, both early
apoptosis (caspase 3/7) and late (Sytox®) apoptosis/necrosis were
determined (Fig. 2C/D). While the initial (2 h) timepoint showed
that polymer grafting slightly increased (p < 0.05) apoptotic and/or
necrotic events in a dose dependent manner, there were no sig-
niﬁcant differences (p > 0.05) from control MLR at any subsequent
timepoint assessed. These data indicate that polymer-induced
apoptosis was not a major contributor to the loss of alloprolifer-
ative response seen in mPEG-modiﬁed MLRs (Fig. 2A).3.3. Inhibition of cellecell interactions via time-lapse microscopy
As demonstrated in Fig. 2B, the immunocamouﬂage of cell sur-
faces signiﬁcantly reduced static cellecell conjugation events.
However, in vitro and in vivo, leukocytes are actively motile cells
forming transient and prolonged focal contacts (minutes to hours)
between lymphocytes and APC (e.g., dendritic cells) [24e27]. To
investigate the general movement and cellecell interaction be-
tween control and polymer-modiﬁed PBMC with APC, time-lapse
microscopy was utilized. Human moDC were matured, activated,
and co-cultured with control or PEGylated allogeneic human PBMC
and photomicrographs were acquired every 20 s for 90 min (Sup-
plemental Movies 1 and 2). Representative micrographs of controland PEGylated PBMC from 0 to 90 min are shown in Fig. 3A/B.
Within 30 min, unmodiﬁed (control) lymphocytes were observed
forming prolonged and frequent contact with the allogeneic moDC
(indicated by arrows) (Fig. 3A; Supplemental Movie 1). In contrast,
PEGylated lymphocytes (20 kDa; 2.0 mM) failed to generate sus-
tained interactions with the allogeneic moDC over the 90 min time
span assessed (Fig. 3B; Supplemental Movie 2). These ﬁndings
suggest that PEGylation may prevent the direct recognition of
foreign alloantigens by decreasing the stability and duration of
cellecell interactions.
Supplementary data related to this article can be found online at
http://dx.doi.org/10.1016/j.biomaterials.2015.09.047.
As noted, both APCs and lymphocytes are highly motile cells
capable of covering fairly large distances in order to search for and
present foreign antigen via cell surface receptors. Indeed, studies
show that 3-dimensional T cell velocities can be as high as 10 mm/
min [28], while dendritic cells average approximately 6.6 mm/min
both in vitro and in vivo [27,29]. However, upon cellecell contact
and recognition of foreign antigens, both lymphocyte and APC cell
mobility decreases [24,25,30,31]. To assess the effects of PEGylation
on cellecell interaction and motility during allogeneic challenge,
the migration of moDC were tracked for 90 min. As demonstrated
in Fig. 3CeD, the superimposed trajectories of the moDCmotility in
the control (n ¼ 34) and PEGylated (n ¼ 28) MLR showed that
moDC migration was signiﬁcantly reduced in the control MLR
(relative to the mPEG-MLR) consequent to prolonged and persis-
tent conjugation to the unmodiﬁed allogeneic PBMC. These obser-
vations support the ﬁndings of both the MLR (Fig. 2A) and cell
Fig. 3. PEGylation decreased cellecell interactions between allogeneic cells. Panel A: Shown are representative micrographs taken at 30 min intervals from a 90 min time-lapse
assay (n ¼ 3). Within 30 min of acquisition, unmodiﬁed lymphocytes were seen forming prolonged contacts with moDC (indicated by arrows). In contrast, lymphocytes PEGy-
lated with 20 kDa SVA-mPEG (2.0 mM) failed to generate sustained interactions with moDC over the time period assessed. Size bar ¼ 10 mm. Panel B: The superimposed trajectories
of moDC movements in the control and PEGylated samples showed that moDC movements were inversely correlated with antigen encounter. The movements of moDC in control
samples showed an overall decrease in the 2-dimensional area covered compared to moDC co-cultured with PEGylated PBMC, demonstrating the loss of cell interactions between
PEGylated lymphocytes and moDC.
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attenuation of essential cellecell interactions between PEGylated
lymphocytes and MoDC.3.4. Effect of polymer grafting on leukocyte activation
In concert, receptor-ligand and cellecell interactions mediate
changes in intracellular signaling cascades with the NFkB tran-
scription factor being a crucial common endpoint in allor-
ecognition, T cell differentiation as well as apoptosis [32]. This also
includes the regulation and production of IL2 as well as other in-
ﬂammatory molecules and growth factors. To assess the effects of
polymer modiﬁcation on cell activation pathways, real-time PCR of
human NFkB signaling targets (RT2 Proﬁler PCR array) were
examined in control and mPEG modiﬁed MLRs (20 kDa; 2.0 mM) at
2, 6 and 24 h relative to resting PBMC. As demonstrated by the
heatmaps shown in Fig. 4, minimal differences in mRNA proﬁles
between the control MLR (C), and mPEG-MLR (P) relative to control
cells were observed at 2 h. Moreover, comparing the mPEG-MLR to
the control MLR (PvC) further demonstrated the lack of differential
changes. However by 6 and 24 h, the control MLR (C) demonstratedsigniﬁcant increases (denoted by increased 'red' to 'orange') in
multiple NFkB signaling targets while the mPEG-MLR remained
quiescent and closely resembled the resting cell signature (i.e.,
'black'). The differences in the control and mPEG-MLRs was further
magniﬁed when the two samples were directly compared to each
other (denoted as PvC) with the mPEG-MLR showing decreased
expression (denoted by 'blue') of multiple NFkB targets. In aggre-
gate, this data suggests a considerable change/decrease in the
activation proﬁle of the mPEG-modiﬁed leukocytes upon allosti-
mulation relative control PBMC. However, not all NFkB targets were
completely abrogated in the mPEG-MLR as mRNA expression
remained somewhat increased compared to resting PBMC.
To better illustrate themRNA differences in the NFkB-dependent
signaling pathways, volcano plots (representing fold-change and
signiﬁcance; both x- and y-axes, respectively) were used to
compare the relative change in mRNA expression (mean values
from 3 independent experiments) of the mPEG-MLR to the control
MLR at 6 and 24 h (Fig. 5). As noted, the mRNA expression of many
inﬂammatory cytokines and chemokines characteristically upre-
gulated during MLRs were considerably decreased in the mPEG-
MLR (black circles) though other mRNA were similarly expressed
Fig. 4. mPEG-MLR demonstrated a global decrease in expression of mRNA involved in
NFkB signal transduction. Mean changes in fold regulation of three independent ex-
periments are shown as heat maps, comparing control MLR vs resting PBMC (C),
mPEG-MLR vs resting PBMC (P) and mPEG-MLR vs control MLR (PvC) at 2, 6 and 24 h.
Genes (listed in left column) responsive to NFkB signal transduction include those
involved in (right column) inﬂammation, immune response, differentiation and
apoptosis.
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statistically signiﬁcant (p < 0.05; denoted by shaded box). For
example, very early in the alloresponse (i.e., 6 h), IL2 and CSF3
produced by lymphocytes and monocytes, respectively, were
signiﬁcantly (p < 0.05) downregulated in mPEG-MLR and by 24 h,
IL1R2, STAT1, IL2 and F3 mRNA were all signiﬁcantly (p < 0.05)
decreased in mPEG-MLR. Although fold-expression of multiple
mRNA targets were downregulated in mPEG-MLR, the relatively
low number of statistically signiﬁcant targets observed may be due
to the increased variability in the alloresponse of disparate donor
PBMC populations during MLRs (ranging from only 1e10% of cells).
However, biologically speaking, the differentially decreased mRNA
expression of various inﬂammatory chemokines and cytokines
(black circles) may be cumulative, creating a decreased inﬂamma-
tory milieu during the mPEG-MLR, thus contributing to the
decreased cell proliferation and differential T cell subset differen-
tiation (see Ref. [13]).
While, we had previously demonstrated that expression of cy-
tokines (e.g., IL2 and INFg) that promote and are the product ofSTAT1 activation were signiﬁcantly downregulated in mPEG-MLR
[13], we wished to further these observations based on the above
qPCR mRNA ﬁndings. To this end, we examined the differential
expression of IL2 receptors (IL2Ra and b) and IL1R2 receptor in
resting, control MLR and mPEG-MLR cells. Increased expression of
high afﬁnity IL2Ra is indicative of the response to IL2 production as
well as an marker of cell activation while IL1R2 is a decoy receptor
that is upregulated in response to inﬂammatory cytokines via NFkB
transduction, to control the biological effects of IL1 during an in-
ﬂammatory immune response [33].
Western blots and mean band intensities for IL2Ra, IL2Rb and
IL1R2 at days 4 and 7 are shown for 3 independent experiments in
Fig. 6AeD for resting PBMC, control MLR and mPEG-MLR. As
shown, the control MLR yielded a signiﬁcant increase (p < 0.05) in
IL2Ra expression on day 7 relative to both resting cells and the
mPEG-MLR (Fig. 6A). Conversely, the mPEG-MLR demonstrated no
signiﬁcant increase in IL2Ra expression relative to resting PBMC on
either day 4 or 7. These protein ﬁndings correlated with the mRNA
data (Figs. 4 and 5), which indicated an upregulation of IL2Ra
mRNA in the control MLR, compared to the mPEG-MLR and sug-
gests an increased receptor expression response to IL2. As expected,
no signiﬁcant differences (p > 0.05) were seen in the constitutively
expressed IL2Rb between resting PBMC and the control and mPEG-
MLR on either day 4 or 7 (Fig. 6B).
As noted in Figs. 4 and 5, mRNA proﬁles indicated that the decoy
receptor IL1R2 was upregulated in control MLRs compared to
mPEG-MLR at 24 h. Since IL1R2 is expressed on both the cell
membrane as well as in secreted form, membrane (Fig. 6C) and
supernatant (Fig. 6D) IL1R2 expression was assessed in resting
PBMC, control-MLR and mPEG-MLR. Western blot analysis
demonstrated a small increase in the expression of IL1R2 in both
the membrane (day 4 and 7) and secreted protein (day 7) in the
control MLR compared to either resting PBMC or the mPEG-
modiﬁed MLR. However this difference did not reach statistical
signiﬁcance in either location or at any of the timepoints assessed.
4. Discussion
Tissue rejection occurs subsequent to the recognition of foreign
antigens, via contact between APC and T cells. Current clinical ap-
proaches utilize tissue matching (HLA and blood typing) as well as
immunosuppressive agents in an effort to attenuate allorecognition
and control the alloresponse [1e6]. However, these practices lead
to both inventory and drug toxicity issues for patients [4,5]. A
recent approach to address these problems has been the bioengi-
neering of allogeneic cells using grafted polymers to camouﬂage
antigenic epitopes and prevent immune recognition (i.e., immu-
nocamouﬂage) [8,9]. However previous PEGylation studies
involved monitoring late events in T cell activation, such as prolif-
eration and cytokine secretion [11e15]. Although valuable, these
studies did not provide crucial information on early leukocyte
events mediating the decreased alloproliferative response
following polymer grafting. Therefore we sought to evaluate the
relationship between surface camouﬂage, cellecell interactions,
intracellular activation pathway (NFkB), and cell death to the
decreased proliferative response seen during an allogeneic
challenge.
Previous biophysical studies indicate that surface camouﬂage is
achieved through both charge and steric camouﬂage of cell surfaces
owing to the large hydrodynamic shielding capability of the neutral
water binding PEG, as well as steric repulsion governed by the
polymer occupying a large 3D surface area [21]. As demonstrated in
this study, membrane grafting of mPEG signiﬁcantly attenuated
antigen recognition of multiple proteins involved in cell adhesion,
allorecognition, costimulation, activation and proliferation (Fig. 1).
Fig. 5. Immunocamouﬂage signiﬁcantly inhibits mRNA expression of inﬂammatory cytokines and chemokines characteristically upregulated by allorecognition. Shown are volcano
plots of mRNA expression of the mPEG-MLR compared to the control-MLR following 6 and 24 h of incubation. Volcano plots illustrate both fold change and signiﬁcance (x- and y-
axes, respectively) between the mPEG-MLR and control-MLR and are derived from three independent experiments (n ¼ 3). Grey shaded area shows targets that displayed both large
magnitude fold changes and statistical (p < 0.05) signiﬁcance.
Fig. 6. Effect of immunocamouﬂage on IL2Ra, IL2Rb and IL1R2 receptor expression. Panels AeB: The expression of the inducible IL2Ra receptor was signiﬁcantly decreased
(p < 0.05) in mPEG-MLR compared to the control-MLR on day 7 (A) Conversely, no signiﬁcant differences were observed between mPEG-MLR and control MLR for the constitutively
expressed IL2Rb (B) Panels C-D: While the IL1R2 receptor [both membrane bound (C) and secreted (D)] did demonstrate an increase in the MLR sample relative to resting PBMC and
the mPEG-MLR, these ﬁndings did not reach statistical signiﬁcance (p > 0.05). Shown as inserts are the western blot results of triplicate experiments (IeIII) and the corresponding
actin loading controls of resting PBMC (a,d), control-MLR (b,e) and 2.0 mM mPEG-MLR (c,f) at days 4 and 7. Blots were analyzed by densitometry and the results are expressed
relative to unmodiﬁed control day 4, which was set to equal 1. Results are expressed as mean ± SEM.
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was dependent on the length of the polymer, the number of lysine
residues (primary binding site of NHS linkers (i.e, SVA)) in a proteinor protein complex and the binding site location spatially relative to
the antibody-binding site [19,21]. Importantly all leukocyte pro-
teins assessed in this study demonstrated signiﬁcant decreases in
D.L. Kyluik-Price, M.D. Scott / Biomaterials 74 (2016) 167e177 175antibody recognition, compared to control cells demonstrating the
global, albeit incomplete, immunocamouﬂage of the cell surface.
Our previous research has shown however, that due to both direct
and indirect camouﬂage of surface epitopes, complete surface
camouﬂage using very high grafting concentrations are not
necessary to exert signiﬁcant biologic/immunologic effects (i.e.
prevent phagocytic recognition of antibody opsonized allogeneic
RBC [19,21]).
Indeed, in this study it was observed that mPEG-modiﬁcation
signiﬁcantly impeded cellecell interactions between PEGylated
PBMC and allogeneic moDC in an MLR (Figs. 2B and 3) leading to a
loss of alloproliferation (Fig. 2A). As schematically illustrated in
Fig. 7, under normal circumstances (left panel) allorecognition be-
tween disparate donor cells undergo multifocal interactions
involving adhesion, allorecognition and costimulation via surface
proteins. Consequent to these events signal transduction occurs
and cell proliferation and/or apoptosis is initiated. Polymer grafting
disrupts the requisite multifocal receptor-ligand events necessary
for cell conjugation (right panel). As denoted by (a) and (b) in Fig. 7,
PEGylation effectively increases the distance of the shear plane
from the membrane surface, obscuring the protein surface charges
beneath a neutral PEG layer thus hindering charge-mediated re-
ceptor-ligand interactions. This charge camouﬂage, coupled with
the steric hindrance of the polymer itself, decreases the stability
and duration of receptor-ligand and cellecell interactions
(Figs. 1,2B,3 and 7) leading to the loss of signal transduction
(Figs. 4e7) and the inhibition of alloproliferation (Fig. 2A).Fig. 7. Mechanisms of inhibition of allorecognition by immunocamouﬂage. In a control M
lymphocytes (LYM) and dendritic cells (APC). The lymphocyte adhesion and antigen prese
arrows). PEGylation of the allogeneic PBMC decreases the stability and duration of initial cell
of membrane proteins. As shown, the bound polymers effectively extend the distance of the s
the neutral PEG layer hindering receptor-ligand interactions. While some receptor-ligand int
to a net loss in the stability and duration of the cellecell interaction and signal transduction.
TCR) important for cell activation during allorecognition are impeded as are intracellular sig
proliferation.Mechanistically, the impact of membrane-grafted polymer on
signal transduction is of critical importance. As shown in this study,
polymer grafting signiﬁcantly downregulated NFkB dependent
mRNAs necessary for allorecognition, cytokine production and
proliferation (Figs. 4e5). The changes in mRNA was reﬂected, at
least in part, by changes in protein expression. As shown in Fig. 6,
the inducible IL2Ra receptor was upregulated in control MLR but
not in the mPEG-MLR. Importantly, the loss of proliferationwas not
due to polymer-mediated cytotoxicity as PEGylation at immuno-
protective concentrations did not induce apoptotic or necrotic
pathways (Fig. 2CeD) and previous studies had demonstrated
normal viability and proliferative potential of modiﬁed human
PBMC and murine splenocytes following polymer grafting
[12,13,19,20].
It is important to note however, that although very signiﬁcant
decreases were seen in CD marker detection, cellecell interactions,
NFkB activation and alloproliferation with the PEGylated cells,
these events were not completely abrogated. Indeed, it is quite
plausible that short dynamic interactions may still be occurring at
some foci of interaction (d). However, consequent to membrane
PEGylation there is disruption in the formation of stable multi-focal
receptor-ligand interactions as indicated by (d) and (e) in Fig. 7. The
altered cellecell interactionsmay lead to the differential expression
of mRNAs (Figs. 4 and 5) noted in the mPEG-modiﬁed cells. The
altered cellecell interaction may also underlay the highly altered T
cell subset differentiation (characterized by signiﬁcantly increased
T regulatory cells and decreased proinﬂammatory T cells) observedLR, signiﬁcant and persistent interactions (black arrows) occur between allogeneic
ntation interactions typically occur at pseudopodial extensions from the APC (white
ecell interactions between lymphocytes due to the global charge and steric camouﬂage
hear plane (a/ b) from the membrane, burying the surface potential gradient beneath
eractions are minimally affected (d), other interactions are strongly inhibited (e) leading
Consequent to this charge/steric interference, the interaction of protein complexes (e.g.,
naling cascades (e.g., NFkB) necessary for cytokine and chemokine signaling and T cell
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While much of the data related to mPEG grafting to proteins,
cells and tissues is positive, some negative ﬁnding have been re-
ported; most related to PEGylated nanocarriers (typically lipo-
somes) [34e37]. For example, Hamad et al. (2008) reported that
PEGylated carbon nanotubes, but not PEGylated liposomes (PEG-
PL) without carbon nanotubes, gave rise to complement activation.
Hamad et al. hypothesized that, at least in part, complement acti-
vation arose from inadequate camouﬂage of the nanotubes them-
selves allowing for adsorption of complement ﬁxing components of
human serum [34]. Similarly the Ishida group in Japan has reported
complement activation and the generation of anti-PEG antibodies
by some formulations of PEGylated liposomes [35e37]. These
studies demonstrated that both complement activation and anti-
PEG antibody production was dependent on what was being
inserted into the liposome (e.g., DNA favors both complement ﬁx-
ation and antibody formation) as the liposomes themselves were
immunologically inert. In these studies, the reactivity of the
PEGylated carrier may be due to speciﬁc or non-speciﬁc adsorption
of plasma proteins to material contained within the PEGylated
liposome. Previous studies from our laboratory have extensively
examined human serum protein adsorption to control and PEGy-
lated latex beads using iTRAQ-MS analysis and established that
PEGylated surfaces reduced nonspeciﬁc adsorption of human
plasma proteins by ~68% while 21% of proteins were unchanged
[21,38]. Of interest however, 11% of the plasma did demonstrate a
PEG-dependent increase in their relative adsorption. Interestingly,
these proteins were collagen or ﬁbrin-like proteins, or proteins
involved in adhesion and binding of collagen-like proteins and
included components of the immune system. Encompassed among
these proteins were components of the C1q (alpha and beta chains)
complement complex that would be capable of initiating comple-
ment activation. Also of importance, not all of the proteins showing
increase ITRAQ-MS adsorption would be detrimental. For example,
a mPEG-dose-dependent increase in the relative abundance of
beta-2-glycoprotein I precursor and thrombospondin 1 were
observed. Beta-2-glycoprotein binds to negatively charged phos-
pholipids and could potentially inhibit the coagulation cascade,
while thrombospondin-1 is a potent inhibitor of T-cell and den-
dritic cell activation. However, of more biologic importance, our
previous studies demonstrated no direct complement activation or
consumption by intact mPEG-modiﬁed human erythrocytes incu-
bated in human sera or in mice inwhich >80% of their red cell mass
were mPEG-RBC [10,39]. Further supporting this observation, mu-
rine transfusion studies demonstrated normal mPEG-RBC in vivo
survival (~50 days; even with repeated transfusions) as well as
normal tissue histology (e.g., spleen and liver) upon necropsy
[10,40,41]. Similarly, extensive in vivo (mouse) studies with PEGy-
lated allogeneic leukocytes showed no evidence of complement
activation. Indeed, PEGylated leukocytes actually appears to favor
the induction of immune tolerance arising from the induction of T
regulatory cells; an event that would not occur in the presence of
signiﬁcant complement activation [13].
The signiﬁcance of these ﬁndings are not simply 'informational'
but are 'translational' in nature. Our studies suggest that polymer-
based bioengineering of donor cells may provide a signiﬁcant
clinical opportunity to attenuate the recognition and rejection of
allogeneic cells and tissues while simultaneously and systemically
reorienting the recipient's immune system towards a tolerogenic
state [12e15]. For example, in transfusion medicine, PEGylated
donor red blood cells may be clinically useful in the chronically
transfused patient in which alloimmunization to non-ABO blood
group antigens poses a signiﬁcant clinical problem - though poly-
mer speciﬁc formulations (size and grafting density) may be
necessary for different blood group antigens [9e14]. Also ofinterest, in murine models, PEGylation of passenger leukocytes in
donor blood products prevented transfusion-associated graft
versus host disease consequent to attenuated allorecognition of the
unmodiﬁed host tissue by the PEGylated donor leukocytes and the
resultant reduction in the in vivo proliferation of the donor lym-
phocytes [12]. Direct PEGylation of small tissue masses are also
possible as shown by the in vivo transplantation of PEGylated
pancreatic islets [15e18]. As shown in these studies, the PEGylated
islets sense blood glucose and secrete insulin normally. But perhaps
the greatest potential for the PEGylation of allogenic cells is the
induction of tolerance. As demonstrated in Wang et al. (2011),
transfusion of PEGylated allogenic leukocyte into mice resulted in a
persistent and systemic modulation of the intact mouse immune
system to a tolerogenic state consequent to an upregulation of
Regulatory T lymphocytes (Foxp3þ Treg) with a concomitant
decrease in inﬂammatory cytokines and effector T cells (e.g.,
proinﬂammatory Th17 cells) [13]. This tolerogenic cellular therapy
approach could potentially be used prior to transplantation of other
allogenic tissues and organs to reduce the risk of acute and chronic
rejection. However care will need to be taken to assess whether the
tolerogenic state could have undesirable consequences such as an
increased risk of tumor growth.
5. Conclusion
The immunocamouﬂage of leukocytes by grafted mPEG signiﬁ-
cantly attenuates recognition, proliferation and the induction of
proinﬂammatory immune responses to allogeneic donor leuko-
cytes both in vitro and in vivo [11e13,20]. The mechanisms under-
lying the loss of allorecognition involves the global camouﬂage of
surface receptors leading to diminished cellecell interaction and
attenuated intracellular signaling that, in aggregate, inhibits the
immune response to allogeneic cells. In contrast to existing phar-
macological approaches that typically target single pathways (often
via cytotoxic means), polymer grafting is non-toxic and, due to the
global nature of immunocamouﬂage, overcomes the biological
redundancy inherent to surface adhesion, costimulatory and
growth receptors and shows no evidence of systemic toxicity. Of
great potential interest is that the loss of allorecognition noted
upon mPEG grafting to allogeneic leukocytes may provide an
avenue to enhance tolerogenic responses prior to or following
transplantation of other allogeneic tissues [13].
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